Clinical Trials
4 trialsNCT07609121 2026-05-27
Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07469956 2026-03-13
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07436741 2026-02-27
Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT07279532 2025-12-12
Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging System
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting